PTC Therapeutics reported positive data for their Huntington’s disease drug, prompting Novartis to make a $1 billion upfront offer to license the drug. PTC will continue ongoing testing and lead discussions with the FDA, while Novartis will take over the pivotal study, manufacturing, and commercialization. The deal includes profit-sharing and milestone payments for PTC. The drug, PTC518, works by reducing levels of a target protein involved in Huntington’s disease. Previous drug trials from other companies have faced setbacks, while Novartis’ own drug candidate for Huntington’s was halted in 2022. The partnership between PTC and Novartis is expected to accelerate the development and commercialization of PTC518.
Source link
Novartis Tries Again in Huntington’s, Putting Up $1B to Partner on a PTC Therapeutics Drug
